Hamburg Acute Renal Injury Study (HARIS)

NCT07338669 · tracked via the Priya Life Science Germany tracker

Sponsor

Universitätsklinikum Hamburg-Eppendorf

Phase

Observational

Started

2025-09-16

Last updated

2026-01-14

Condition(s) studied

Acute Kidney InjuryAcute Kidney Injury (AKI)

Study summary

The Hamburg Acute Renal Injury Study (HARIS) is a prospective observational cohort study aimed at investigating the mechanisms, risk factors, and clinical determinants of acute kidney injury (AKI) trajectories and consequences.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Hospitalized individuals with acute kidney injury (AKI), defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria or hospitalized individuals with acute illness who have not developed AKI (control group) * Age ≥ 18 years at time of enrollment * Personally signed informed consent Exclusion Criteria: * None

Primary outcome measure(s)

Kidney Function Recovery after AKI — assessed at discharge, 3-months after discharge, and annual follow-up
Improvement of kidney function after acute kidney injury, defined by partial or complete return of the kidney function toward baseline values
Persistent Kidney Function Decline — assessed at discharge, 3-months after discharge, and annual follow-up
Sustained impairment of kidney function following acute kidney injury, characterized by incomplete recovery and persistently reduced kidney function over follow-up.
Development or Progression of Chronic Kidney Disease — assessed at 3-months after discharge, and annual follow-up
New onset or worsening of chronic kidney disease during follow-up, assessed based on changes in kidney function over time.
End-stage kidney disease (ESKD) — assessed at discharge, 3-months after discharge, and annual follow-up
Occurrence of ESKD, characterized by the initiation of maintenance kidney replacement therapy, kidney transplantation or a persistent eGFR \< 15 ml/min/1.73m2
Renal mortality — assessed at discharge, 3-months after discharge, and annual follow-up
Death attributable to kidney-related causes as determined by medical record review.
Cardiovascular Outcomes — assessed at discharge, 3-months after discharge, and annual follow-up
cardiovascular death, myocardial infarction, heart failure, arrhythmia, stroke

Trial sites (1)

Facility	City	Region	Status
Universitätsklinikum Hamburg-Eppendorf	Hamburg	Germany	Recruiting

More Universitätsklinikum Hamburg-Eppendorf trials in Germany

External Validation of the MASCAN Score for the Classification of Difficult Mask Ventilation Recruiting

Characterisation of phenotYpes in aCute Heart faiLure patiEnts Recruiting

Prospective Registry and Biobank for Long-term Observational Studies in Adult Patients with Pulmonary Hypertension Recruiting

Proof of Concept Human Study: Dietary Intervention to Modify Intestinal Inflammation in IBD Active, not recruiting

Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor Recruiting

Other trials for the same condition

Remote Ischemic Preconditioning in Septic Patients Recruiting

Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI ) Recruiting

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. Recruiting

Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis Recruiting

Analysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07338669 on ClinicalTrials.gov ↗ ← All trials in Germany